Retatrutide
Retatrutide
Also known as: LY3437943, Triple G, GGG Agonist
Overview
Key Facts
Primary Goal: Research and therapeutic applications of Retatrutide
GLP-1 receptor agonism suppresses appetite and enhances insulin secretion. GIP receptor agonism improves fat metabolism and insulin sensitivity.
Dosing Information
~6 days
1–12 mg
Once weekly
Ongoing / indefinite under medical supervision
Benefits
- Record-breaking weight loss (up to 24% at 48 weeks in Phase 2)
- Triple receptor targeting for comprehensive metabolic improvement
- Significant reduction in liver fat (MASLD/MASH)
- Improved glycemic control and lipid profiles
- Potential cardiovascular benefits
- Preserves lean muscle mass during weight loss
- Once-weekly dosing for simplicity
Side Effects
Mechanism of Action
GLP-1 receptor agonism suppresses appetite and enhances insulin secretion
GIP receptor agonism improves fat metabolism and insulin sensitivity
Glucagon receptor agonism increases energy expenditure and hepatic fat oxidation
Triple agonism produces synergistic effects on weight and metabolism
Contraindications
Do not use this peptide if any of the following apply:
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Severe hepatic impairment
- History of pancreatitis
- Pregnancy or breastfeeding
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Phase 2 results published in NEJM showed retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks, with 26% of participants losing over 30% of body weight — the highest ever reported in a clinical trial. A sub-study demonstrated 86% relative reduction in liver fat. Multiple Phase 3 trials (TRIUMPH programme) are underway across obesity, type 2 diabetes, and MASH indications. Eli Lilly anticipates potential FDA submission by 2026.
Frequently Asked Questions
Common questions about Retatrutide
UK-Specific Information
Exclusive data points and guidance for UK residents using Retatrutide
UK Lab Testing
UK Lab Testing
Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.
Share on TikTok
Generate a trackable link to share this peptide information on TikTok